Page last updated: 2024-09-02

bifendate and Triple Negative Breast Neoplasms

bifendate has been researched along with Triple Negative Breast Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Chen, Y; Gu, X; Li, C; Li, J; Liao, R; Qi, Q; Wang, F; Wang, X; Wu, D; Xiong, G; Zhang, B; Zhou, X	1

Other Studies

1 other study(ies) available for bifendate and Triple Negative Breast Neoplasms

Article	Year
N-3, a novel synthetic derivative of bifendate, inhibits metastasis of triple-negative breast cancer via decreasing p38-regulated FOXC1 protein stability. Biochemical pharmacology, 2023, Volume: 215 Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithelial-Mesenchymal Transition; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Triple Negative Breast Neoplasms	2023

Article

Year

N-3, a novel synthetic derivative of bifendate, inhibits metastasis of triple-negative breast cancer via decreasing p38-regulated FOXC1 protein stability.

Biochemical pharmacology, 2023, Volume: 215

Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithelial-Mesenchymal Transition; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Triple Negative Breast Neoplasms

2023